Which peptides are used for immune support and inflammation?

The core immune modulator is Thymosin Alpha-1, used for chronic inflammation, frequent illness, and immune balance. KPV is the anti-inflammatory anchor, especially for gut-driven inflammation. BPC-157 supports gut inflammation, VIP targets complex chronic inflammatory states like CIRS, and Selank helps when stress is suppressing immunity. The right choice depends on what's driving the inflammation.

Is it safe to use immune peptides with an autoimmune condition?

Immune modulators in autoimmune disease require physician supervision, not self-direction — stimulating an already-dysregulated immune system can be counterproductive. Thymosin Alpha-1 in particular is flagged for physician coordination in autoimmune contexts, and is suppressed entirely in active cancer, where immune stimulation must involve an oncologist.

What is the best peptide for gut inflammation?

KPV and BPC-157 are the gut-focused choices. KPV is a potent anti-inflammatory acting through NF-kB, and BPC-157 heals the gut lining directly. When intake shows gut symptoms driving inflammation, these are the anchors — often together.

Are immune peptides FDA-approved?

Most are investigational research compounds in the U.S. Thymosin Alpha-1 is approved in some countries but not FDA-approved for general use; VIP's synthetic form has orphan-drug status for specific lung indications only. All should be used under physician supervision.

Immune & Inflammatory Peptides — Res…

Name: Immune & Inflammatory Peptides — Research Hub
Creator: Dr. Scott DelBoccio, DMD

The Peptide Evidence Index
See how all 34 peptides rank by the strength of real human evidence — one honest scorecard.

View the Index →

Why This Hub Exists

"Anti-inflammatory" isn't one decision

The immune system doesn't have a single dial. Some peptides calm inflammation; others stimulate a sluggish immune response; and pushing the wrong direction can make things worse — dangerously so in autoimmune disease or cancer. That's why this category, more than most, is defined by its screens. The right compound depends on what's driving the problem and what your history rules out.

The core ideaMatch the compound to the driver: gut inflammation, systemic inflammation, stress-suppressed immunity, or a complex chronic inflammatory syndrome each point somewhere different. And screen hard first — autoimmune and cancer histories change everything here.

The Landscape

The compounds, by role

Anchor · Immune Modulator

Thymosin Alpha-1

Bidirectional immune regulation

The primary immune modulator — for chronic inflammation, frequent illness, and immune balance. Anchored when CRP is elevated. Flagged in autoimmunity; suppressed in active cancer.

Anchor · Anti-Inflammatory

KPV

α-MSH tripeptide · NF-κB

The anti-inflammatory anchor, especially for gut-driven inflammation. Calms the inflammatory signaling behind IBD/IBS-type presentations.

Conditional

BPC-157

Gut healing · brain-gut axis

Added when gut inflammation is a driver — repairs the gut lining directly, pairs with KPV. (Cancer history: avoid — angiogenic.)

Conditional

VIP

CIRS / mold / long COVID

For complex chronic inflammatory states — CIRS, mold biotoxin illness, neuro-inflammation — as the final step of a sequenced protocol, not a first move.

Conditional

LL-37

Cathelicidin · antimicrobial

Host-defense peptide with antimicrobial and wound-healing roles; relevant where infection or dysbiosis drives the inflammatory picture.

Conditional

Selank

Stress-immune axis

Added when stress is suppressing immunity — the anxiolytic that addresses the stress dimension of a run-down, frequently-ill state.

The Differentiator

The driver decides the compound

Immune / Inflammatory Selection Logic

What's driving the inflammation determines what gets used.

If CRP elevated on labs

→

Thymosin Alpha-1 anchors — always, when inflammation is confirmed.

If gut symptoms drive it

→

KPV + BPC-157 — calm and heal the gut.

If stress-suppressed immunity

→

Add Selank — address the stress driver.

If CIRS / mold / long-COVID picture

→

VIP — but only after protocol prerequisites are complete.

Hard screens: autoimmune disease → immune modulators flagged for physician coordination · active cancer → Thymosin Alpha-1 suppressed (immune stimulation needs an oncologist).

The screen that matters most hereImmune modulation is not a "more is better" category. In autoimmune disease, stimulating an already-overactive immune system can backfire — these compounds require physician coordination, not a forum protocol. In active cancer, immune stimulation belongs entirely to your oncologist.

Mechanism, Plainly

Calm, defend, or rebalance

Thymosin Alpha-1 rebalances

It's bidirectional — it can up- or down-regulate immune activity toward balance, which is why it's used for both frequent illness (immune too weak) and chronic inflammation (immune misdirected).

KPV calms the inflammatory signal

Derived from α-MSH, KPV suppresses NF-κB — a master switch of inflammation — which is why it's particularly effective on gut-driven inflammatory states.

VIP resolves stuck inflammation

Shifts inflammatory macrophages toward a regulatory phenotype and helps re-regulate a disordered immune response — the basis for its use in complex chronic inflammatory syndromes.

Gut and stress are upstream levers

Much systemic inflammation originates in the gut or is amplified by stress. That's why BPC-157 (gut) and Selank (stress) show up as conditional supports — they treat the source, not just the symptom.

Evidence Snapshot

What the research shows

Compound	Role	Status & evidence
Thymosin Alpha-1	Immune modulator	Approved in some countries; used clinically for immune indications. Not FDA-approved for general use in the U.S.
KPV	Anti-inflammatory	Research compound; preclinical support for anti-inflammatory and gut-mucosal effects.
VIP	Immune regulator	Synthetic form (aviptadil) has orphan-drug status for specific lung indications; CIRS use is observational, not FDA-validated.
LL-37	Host defense	Research compound; antimicrobial and wound-healing mechanisms studied preclinically.

Safety Screen

What gets checked first

Autoimmune disease. Immune modulators flagged for physician coordination — stimulating a dysregulated immune system can worsen it.
Active cancer. Thymosin Alpha-1 suppressed; any immune stimulation requires oncology involvement.
Cancer history (BPC-157). The gut-support compound is angiogenic — avoid with cancer history.
VIP prerequisites. For CIRS, VIP is the last step — using it before binders and colonization are handled leads to failure.
Undiagnosed chronic inflammation. Elevated inflammation deserves a workup — it can signal serious conditions a peptide would only mask.
Source quality. Unregulated research-grade sourcing — certificate of analysis essential.

Common Questions

Immune peptide questions answered

What's the main immune peptide?

Thymosin Alpha-1 — a bidirectional immune modulator used for chronic inflammation, frequent illness, and immune balance, anchored when CRP is elevated. KPV is the anti-inflammatory partner, especially for gut-driven inflammation.

Can I use these with an autoimmune condition?

Only under physician coordination. Immune modulators can worsen a dysregulated immune system, so autoimmune disease is a flag for specialist oversight, not a green light. This is one of the clearest cases where the screen matters more than the compound.

What helps gut inflammation specifically?

KPV and BPC-157 — KPV calms the inflammatory signaling (NF-κB) and BPC-157 heals the gut lining. When intake points to gut-driven inflammation, they're the anchors, often used together.

Where does VIP fit?

For complex chronic inflammatory states — CIRS, mold illness, long-COVID neuro-inflammation. Critically, it's the final step of a sequenced protocol, not a starting point; used first, it commonly fails.

Not Sure Where You Fit?

Take the 60-second quizAnswer a few questions and get honest, clinician-built education matched to your goal — then a personalized report. No hype, no prescription. Which peptide is right for you? →

About the Author

Dr. Scott DelBoccio, DMD

Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on peptide pharmacology. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked — every hub reflects an independent synthesis of the primary literature and the same selection logic that drives the platform's personalized reports. No products are sold on this site.

Full Disclaimer

This hub is for educational and scientific purposes only and does not constitute medical advice, diagnosis, or treatment. The compounds discussed are research/investigational; immune modulation carries real risks in autoimmune disease and cancer and must involve appropriate specialist supervision. Chronic inflammation and frequent illness can signal conditions requiring professional evaluation. PeptideReport.ai does not manufacture, sell, or endorse any preparation. Content addresses adults 21 and older. Evidence and regulatory status continue to evolve.